Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spartalizumab + LAG525 Combinations in TNBC
NCT03742349Phase 1Terminated
- Sponsor
- Novartis
- Start
- Jan 2019
- Primary completion
- Feb 2023
- Modality
- Prophylactic Vaccines, Immune Checkpoint Inhibitors, Fragment-Derived Small Molecules
- Countries
- 9
01
Overview
Phase 1, open-label trial of spartalizumab, ieramilimab, taminadenant, capmatinib, lacnotuzumab and 1 more in triple negative breast cancer (TNBC) (4 arms), sponsored by Novartis. Primary endpoints: Incidence of Adverse Events and Serious Adverse Events at 18 months, Severity of Adverse Events and Serious Adverse Events at 18 months and 4 more. Started Jan 2019; status: terminated.
02
Drugs
spartalizumabieramilimabtaminadenantcapmatiniblacnotuzumab
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03742349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03742349.